Indivior PLC (INDV)
| Market Cap | 1.73B |
| Revenue (ttm) | 1.17B |
| Net Income (ttm) | -62.00M |
| Shares Out | 124.77M |
| EPS (ttm) | -0.48 |
| PE Ratio | n/a |
| Forward PE | 13.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,723,127 |
| Open | 13.53 |
| Previous Close | 13.69 |
| Day's Range | 13.47 - 13.98 |
| 52-Week Range | 7.33 - 16.50 |
| Beta | 0.25 |
| Analysts | Strong Buy |
| Price Target | 14.50 (+3.94%) |
| Earnings Date | Jul 24, 2025 |
About INDV
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX T... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for INDV stock is "Strong Buy." The 12-month stock price forecast is $14.5, which is an increase of 3.94% from the latest price.
News
Indivior Appoints Tony Kingsley to the Board of Directors
RICHMOND, Va. , June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, eff...
Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users
A post-hoc analysis demonstrates that buprenorphine exposure with 300 mg SUBLOCADE® (buprenorphine extended-release) may improve treatment outcomes among opioid use disorder (OUD) patients with heavy ...
Indivior to delist from London Stock Exchange, maintain Nasdaq listing
Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align...
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
SLOUGH, England and RICHMOND, Va. , June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("O...
Indivior Announces Patrick Barry as Chief Commercial Officer
Seasoned commercial executive with more than 30 years of pharmaceutical experience RICHMOND, Va. , May 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patri...
Indivior to Participate in Upcoming Investor Events
RICHMOND, Va. , May 13, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ/LSE: INDV) today announced that it will participate in the following investor events: Jefferies Global Healthcare Conference – New Yor...
New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy
SUBLOCADE use during pregnancy showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates RICHMOND, Va., May 1, 2025 /PRNewswire/ -- Indivio...
Indivior: Trying To Break Addiction
Indivior PLC's stock has seen headwinds recently due to increasing competition and poor performance but has potential for recovery with a new CEO and strategic changes. Sublocade, Indivior's key produ...
Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript
Indivior PLC (NASDAQ:INDV) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Jason Thompson - Head, IR Mark Crossley - CEO Ryan Preblick - CFO Conference Call Participan...
Indivior Announces Q1 2025 Financial Results
SLOUGH, United Kingdom and RICHMOND, Va. , April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025.
Indivior Announces Further Changes to Board of Directors
RICHMOND, Va. , March 4, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) ("Indivior" or the "Company") today announced that, further to the announcement on December 17, 2024 of certain Director...
UK's Indivior appoints Joe Ciaffoni as CEO
British drugmaker Indivior on Thursday said it appointed Joe Ciaffoni as its new CEO, replacing current boss Mark Crossley.
Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer
RICHMOND, Va. , Feb. 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) has appointed Joe Ciaffoni, currently an Independent Non-Executive Director of the Company, as Chief Executive Officer.
Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection
Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE ® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) RICHMOND, Va....
Indivior PLC (INDV) Q4 2024 Earnings Call Transcript
Indivior PLC (INDV) Q4 2024 Earnings Call Transcript
European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat
Indivior Plc INDV stock plunged following the company's fiscal year 2025 guidance that fell short of Street expectations.
UK's Indivior forecasts 17% decline in 2025 revenue
British drugmaker Indivior on Thursday projected a 17% decline in 2025 net revenue at the midpoint of its forecast range, partly hurt by sluggish sales of its film-form medication-assisted therapy for...
Indivior Announces FY and Q4 2024 Financial Results
SLOUGH, United Kingdom and RICHMOND, Va. , Feb. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending December 31, 2024.
Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes
RICHMOND, Va. , Feb. 12, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative...
Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024
Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered ...
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
RICHMOND, Va. , Nov. 7, 2024 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) the Board of Directors (the "Board") of Indivior plc ("Indivior" or the "Company") notes the publication today of a lette...
Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month
RICHMOND, Va., Oct. 30, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV), in recognizing Substance Abuse Prevention Month, provides an update on key findings from the last year that demonstrate th...
Indivior PLC (INDV) Q3 2024 Earnings Call Transcript
Indivior PLC (NASDAQ:INDV) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ET Company Participants Jason Thompson - Head, IR Mark Crossley - CEO Christian Heidbreder - Chief Scientific Offi...
Indivior Announces Q3 2024 Financial Results
SLOUGH, United Kingdom and RICHMOND, Va. , Oct. 24, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending September 30, 2024.
Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025
Indivior is a $970m small-cap facing to transitory headwinds resulting in extremely negative sentiment and fascinatingly low valuation. Due to the extreme mis-pricing I argue Indivior offers investors...